Insmed to Present R&D Strategy, Pipeline at March TD Cowen and Leerink Conferences

Insmed to present R&D strategy and pipeline at two March investor conferences

Insmed Inc. says company management will present its clinical and research strategy at two industry conferences in March 2026, using the events to showcase its pipeline of pulmonary and inflammatory therapies. Executives are scheduled to speak at the 46th Annual TD Cowen Healthcare Conference in Boston on March 2 at 9:50 a.m. ET and at the Leerink Partners Global Healthcare Conference in Miami on March 10 at 8:00 a.m. ET. Both presentations are webcast live from the investor relations section of www.insmed.com and are archived for 30 days following the live events.

The company frames the appearances as an opportunity to detail a portfolio that spans approved therapies for chronic, debilitating lung diseases and mid‑ to late‑stage investigational programs, along with earlier-stage work in multiple advanced modalities. Insmed highlights active development in gene therapy and AI‑driven protein engineering, as well as investments in protein manufacturing, RNA end‑joining and synthetic rescue technologies. Management intends to reiterate how these programs align with the company’s mission to deliver first- and best‑in‑class treatments for patient communities with high unmet need.

Insmed uses the conference platform to emphasize its ongoing R&D investment, global collaborations and commercial execution plans as part of a broader push to sustain innovation and patient‑centred development. The company underscores a people‑first identity, noting a global footprint across the United States, Europe and Japan, and says it will discuss how scientific progress and operational expansion support the goal of translating early science into clinical and commercial outcomes.

Company recognition, outreach and logistics

In its release, Insmed notes industry recognition for workplace culture, including five consecutive years as the No. 1 Science Top Employer, and invites stakeholders to follow corporate updates on LinkedIn, Instagram, YouTube and X. The company encourages attendees and the media to access live webcasts and archived replays via its investor relations site.

For additional information, Insmed provides investor and media contacts: Bryan Dunn, Vice President, Investor Relations, at (646) 812‑4030 or [email protected], and Claire Mulhearn, Vice President, Corporate Communications, at (862) 842‑6819 or [email protected]. The company issues the announcement as part of ongoing efforts to communicate scientific progress and corporate strategy to stakeholders.